You just read:

Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers

News provided by

Daiichi Sankyo Company, Limited

Sep 20, 2018, 08:00 ET